Biotron Limited · ASX:BIT
Biotron — Investor Presentation (October 2020)
11 slides from Biotron's investor presentation, Oct 14, 2020
Slide 1: ASX cover letter: Presentation to Investors
Level 2, 66 Hunter Street Sydney NSW 2000 Tel: (61-2) 9300 3344 Fax: (61-2) 9221 6333 E-mail: pnightingale@biotron.com.au For personal use only Website: www.biotron.com.au 14 October 2020 The Manager Companies ASX Limited 20 Bridge Street Sydney NSW 2000 (11 pages by email) Dear Madam PRESENTATION T
Slide 2: Biotron Limited Investor Update October 2020
For personal use only BIOTRON LIMITED (ASX:BIT) Investor Update October 2020
Slide 3: Forward Looking Statements
Forward Looking Statements For personal use only This presentation may contain forward‐looking statements with respect to the financial condition, results and business achievements/performance of Biotron Limited (ACN 086 399 144) and certain of the plans and objectives of its management. These state
Slide 4: Biotron Overview
Biotron Overview For personal use only • Clinical stage company developing small molecule drugs targeting big health problems: • HIV‐1, Hepatitis B, COVID‐19, Dengue and others • Positive data in trials to date including a successful HIV‐1 Phase 2 trial • Potential for improved health outcomes and e
Slide 5: Key Achievements in Last Months
Key Achievements in Last 12 Months For personal use only • Raised $5.8 million in Dec 2019 from exercise of BITOB options • Reported positive results from the Phase 2 HIV‐1 clinical trial of BIT225 • Set up world‐class Advisory Board of international HIV‐1 experts • Appointed US‐based Chief Medical
Slide 6: SARS-CoV-2
SARS‐CoV‐2 For personal use only • Biotron’s core expertise is designing drugs to target a key viral protein found on a range of different viruses • Biotron researchers were first to identify and report on this protein (E protein) on coronaviruses (Refer Wilson et al, Virology 353 (2006):294‐306) •
Slide 7: HIV-1 Eradication
HIV‐1 Eradication For personal use only Why is HIV‐1 eradication necessary? • Current antiretroviral drugs (ART) do not eradicate the virus • Long‐term health implications eg. HAND, immune activation, increase in malignancies and chronic diseases, drug‐drug interactions • Major burden on healthcare
Slide 8: Significance of Results from BIT225 Phase Trial
Significance of Results from BIT225 Phase 2 Trial For personal use only • BIT225, a small molecule drug, combines direct‐acting antiviral activity with immune modulatory effects • This is a unique mode of action; no other antiviral drug combines these two treatment paradigms • BIT225 targets a key v
Slide 9: Outlook for 2020/2021 FY
Outlook for 2020/2021 FY For personal use only • HIV‐1 program is the prime focus • Conferring with KOLs/advisory group to map out late‐stage clinical development • Progressing discussions with potential partners • Continuing screening to identify lead anti‐SARS‐CoV‐2 compound(s) to progress to next
Slide 10: Financial Information
Financial Information For personal use only Key Financial Metrics Ticker Code ASX: BIT Share Price (13/10/2020) A $0.105 Market Cap A $70 million 12 Month Trading Range A $0.05 – 0.185 Shares Outstanding 702 million Cash Position (09/2020) A $7.66 million Board Michael Hoy Non‐executive Chairman Mic
Slide 11: Biotron Limited contact
For personal use only BIOTRON LIMITED (ASX:BIT) Michelle Miller Managing Director mmiller@biotron.com.au www.biotron.com.au